Institut for Specialistuddannelse i Schema Terapi ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.3% 1.3% 1.3% 1.3% 1.3%  
Bankruptcy risk  0.0% 8.6% 8.1% 12.1% 11.3%  
Credit score (0-100)  0 27 29 18 21  
Credit rating  N/A BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 15.2 10.7 -5.5 27.4  
EBITDA  0.0 15.2 10.7 -5.5 27.4  
EBIT  0.0 15.2 10.7 -5.5 27.4  
Pre-tax profit (PTP)  0.0 9.9 8.8 -6.0 26.7  
Net earnings  0.0 7.7 6.8 -6.0 21.7  
Pre-tax profit without non-rec. items  0.0 9.9 8.8 -6.0 26.7  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 47.7 54.6 48.6 70.3  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 262 276 244 85.3  

Net Debt  0.0 -262 -161 -104 -85.3  
 
See the entire balance sheet

Volume 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 15.2 10.7 -5.5 27.4  
Gross profit growth  0.0% 0.0% -29.5% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 262 276 244 85  
Balance sheet change%  0.0% 0.0% 5.1% -11.4% -65.1%  
Added value  0.0 15.2 10.7 -5.5 27.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 2.0 -1.0 1.0  

Profitability 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 5.8% 4.0% -2.1% 16.6%  
ROI %  0.0% 31.9% 21.0% -10.6% 46.1%  
ROE %  0.0% 16.2% 13.4% -11.7% 36.6%  

Solidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 49.0% 39.0% 46.4% 84.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -1,725.2% -1,503.1% 1,914.3% -311.1%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 5.3 3.2 4.4 6.6  
Current Ratio  0.0 1.2 1.2 1.2 5.7  
Cash and cash equivalent  0.0 262.4 161.1 104.4 85.3  

Capital use efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 47.7 54.6 48.6 70.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0